These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32492013)

  • 1. [Maintenance of Plasmid Expression in vivo Depends Primarily on the CpG Contents of the Vector and Transgene].
    Bruter AV; Kalashnikova MV; Prytyko AP; Belyavsky AV
    Mol Biol (Mosk); 2020; 54(3):487-496. PubMed ID: 32492013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of plasmid-mediated expression of transgenes in human mesenchymal stem cells depends primarily on CpG levels of both vector and transgene.
    Bruter AV; Kandarakov OF; Belyavsky AV
    J Gene Med; 2018 Feb; 20(2-3):e3009. PubMed ID: 29424052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression.
    Mitsui M; Nishikawa M; Zang L; Ando M; Hattori K; Takahashi Y; Watanabe Y; Takakura Y
    J Gene Med; 2009 May; 11(5):435-43. PubMed ID: 19291673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
    Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
    J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses.
    Reyes-Sandoval A; Ertl HC
    Mol Ther; 2004 Feb; 9(2):249-61. PubMed ID: 14759809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation.
    Chen ZY; Riu E; He CY; Xu H; Kay MA
    Mol Ther; 2008 Mar; 16(3):548-56. PubMed ID: 18253155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable Transgene Expression Driven by CpG-Free and -Containing Promoters in Plasmid DNA with CpG-Free Backbone.
    Suzuki T; Goda T; Kamiya H
    Biol Pharm Bull; 2018; 41(9):1489-1493. PubMed ID: 30175785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
    Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
    Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo.
    Riu E; Grimm D; Huang Z; Kay MA
    Hum Gene Ther; 2005 May; 16(5):558-70. PubMed ID: 15916481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Building mosaics of therapeutic plasmid gene vectors.
    Tolmachov OE
    Curr Gene Ther; 2011 Dec; 11(6):466-78. PubMed ID: 22023476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomy of plasmid DNAs with anti-silencing elements.
    Kanda GN; Miyamoto S; Kobayashi M; Matsuoka I; Harashima H; Kamiya H
    Int J Pharm; 2014 Apr; 464(1-2):27-33. PubMed ID: 24472643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides.
    Hodges BL; Taylor KM; Joseph MF; Bourgeois SA; Scheule RK
    Mol Ther; 2004 Aug; 10(2):269-78. PubMed ID: 15294174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of intrinsic immunogenicity of reporter and insulin gene therapy plasmids.
    Ratanamart J; Huggins CG; Kirby JA; Shaw JA
    J Gene Med; 2007 Aug; 9(8):703-14. PubMed ID: 17595049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional plasmid DNAs with a CpG-containing backbone achieve durable transgene expression in mouse liver.
    Suzuki T; Wakao Y; Goda T; Kamiya H
    J Gene Med; 2020 Jan; 22(1):e3138. PubMed ID: 31696985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design.
    Kosovac D; Wild J; Ludwig C; Meissner S; Bauer AP; Wagner R
    Gene Ther; 2011 Feb; 18(2):189-98. PubMed ID: 20944679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pEPito: a significantly improved non-viral episomal expression vector for mammalian cells.
    Haase R; Argyros O; Wong SP; Harbottle RP; Lipps HJ; Ogris M; Magnusson T; Vizoso Pinto MG; Haas J; Baiker A
    BMC Biotechnol; 2010 Mar; 10():20. PubMed ID: 20230618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro.
    Lu J; Zhang F; Kay MA
    Mol Ther; 2013 May; 21(5):954-63. PubMed ID: 23459514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control and augmentation of long-term plasmid transgene expression in vivo in murine muscle tissue and ex vivo in patient mesenchymal tissue.
    Morrissey D; van Pijkeren JP; Rajendran S; Collins SA; Casey G; O'Sullivan GC; Tangney M
    J Biomed Biotechnol; 2012; 2012():379845. PubMed ID: 22811595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX.
    Schüttrumpf J; Milanov P; Abriss D; Roth S; Tonn T; Seifried E
    Hum Gene Ther; 2011 Jan; 22(1):101-6. PubMed ID: 20677911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector.
    Ogueta SB; Yao F; Marasco WA
    Mol Med; 2001 Aug; 7(8):569-79. PubMed ID: 11591893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.